TLX:NSD-Telix Pharmaceuticals Limited (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 16.6

Change

+0.40 (+2.47)%

Market Cap

USD 5.23B

Volume

0.07M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 65.38B
ARGX argenx NV ADR

N/A

USD 34.54B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 32.75B
ONC BeiGene, Ltd.

N/A

USD 27.70B
SMMT Summit Therapeutics PLC

N/A

USD 27.07B
RPRX Royalty Pharma Plc

N/A

USD 18.40B
INSM Insmed Inc

N/A

USD 11.84B
INCY Incyte Corporation

N/A

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 11.29B

ETFs Containing TLX

E907:XETRA Lyxor 1 MDAX (DR) UCITS E.. 5.01 % 0.00 %

N/A

USD 0.13B
C007:XETRA Amundi Index Solutions - .. 5.01 % 0.00 %

N/A

USD 0.16B
XDGM:F db x-trackers Mittelstand.. 4.43 % 0.00 %

N/A

USD 0.13B
EXID:XETRA iShares MDAX® UCITS ETF .. 4.03 % 0.00 %

N/A

USD 1.12B
ELF1:XETRA Deka MDAX® UCITS ETF 3.95 % 0.00 %

N/A

USD 0.35B
EXS3:XETRA iShares MDAX® UCITS ETF .. 3.95 % 0.00 %

N/A

USD 1.12B
MVE:AU VanEck Vectors Australian.. 2.75 % 0.00 %

N/A

USD 0.34B
36BA:XETRA iShares $ Corp Bond ESG U.. 1.61 % 0.00 %

N/A

USD 0.30B
LDEU:LSE L&G Quality Equity Divide.. 1.21 % 0.00 %

N/A

USD 0.07B
LGGE:XETRA L&G Quality Equity Divide.. 1.21 % 0.00 %

N/A

USD 0.03B
FNDC Schwab Fundamental Intern.. 0.19 % 0.39 %

N/A

USD 2.84B
FEP First Trust Europe AlphaD.. 0.00 % 0.80 %

N/A

USD 0.23B
FGM First Trust Germany Alpha.. 0.00 % 0.80 %

N/A

USD 0.01B
FPA First Trust Asia Pacific .. 0.00 % 0.80 %

N/A

USD 0.01B
FTGG:XETRA First Trust Germany Alpha.. 0.00 % 0.00 %

N/A

USD 6.77M
XDGM:XETRA db x-trackers Mittelstand.. 0.00 % 0.00 %

N/A

N/A
DEAM:XETRA Invesco MDAX® UCITS ETF .. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.79% 78% C+ 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.79% 78% C+ 78% C+
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 5.23B 95% A 89% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.